Richard W Tsang

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5978596/publications.pdf

Version: 2024-02-01

44069 51608 7,858 133 48 86 citations h-index g-index papers 135 135 135 6475 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	Localized Mucosa-Associated Lymphoid Tissue Lymphoma Treated With Radiation Therapy Has Excellent Clinical Outcome. Journal of Clinical Oncology, 2003, 21, 4157-4164.	1.6	370
2	The effects of surgery, radioiodine, and external radiation therapy on the clinical outcome of patients with differentiated thyroid carcinoma. Cancer, 1998, 82, 375-388.	4.1	351
3	Modern Radiation Therapy for Extranodal Lymphomas: Field and Dose Guidelines From the International Lymphoma Radiation Oncology Group. International Journal of Radiation Oncology Biology Physics, 2015, 92, 11-31.	0.8	303
4	Second Primary Malignancy Risk After Radioactive Iodine Treatment for Thyroid Cancer: A Systematic Review and Meta-analysis. Thyroid, 2009, 19, 451-457.	4.5	296
5	Solitary plasmacytoma treated with radiotherapy: Impact of tumor size on outcome. International Journal of Radiation Oncology Biology Physics, 2001, 50, 113-120.	0.8	253
6	Clinical management and outcome of papillary and follicular (differentiated) thyroid cancer presenting with distant metastasis at diagnosis. Cancer, 2007, 110, 1451-1456.	4.1	246
7	A comparison of different staging systems predictability of patient outcome. Cancer, 1997, 79, 2414-2423.	4.1	237
8	An Updated Systematic Review and Commentary Examining the Effectiveness of Radioactive Iodine Remnant Ablation in Well-Differentiated Thyroid Cancer. Endocrinology and Metabolism Clinics of North America, 2008, 37, 457-480.	3.2	230
9	Outcomes and patterns of failure in solitary plasmacytoma: A multicenter Rare Cancer Network study of 258 patients. International Journal of Radiation Oncology Biology Physics, 2006, 64, 210-217.	0.8	225
10	Radiation therapy for pituitary adenoma: Treatment outcome and prognostic factors. International Journal of Radiation Oncology Biology Physics, 1994, 30, 557-565.	0.8	203
11	Primary CNS Lymphoma of T-Cell Origin: A Descriptive Analysis From the International Primary CNS Lymphoma Collaborative Group. Journal of Clinical Oncology, 2005, 23, 2233-2239.	1.6	188
12	Longâ€ŧerm outcome in localized extranodal mucosaâ€associated lymphoid tissue lymphomas treated with radiotherapy. Cancer, 2010, 116, 3815-3824.	4.1	172
13	Stage I and II malt lymphoma: results of treatment with radiotherapy. International Journal of Radiation Oncology Biology Physics, 2001, 50, 1258-1264.	0.8	167
14	Prognostic factors in solitary plasmacytoma of the bone: a multicenter Rare Cancer Network study. BMC Cancer, 2006, 6, 118.	2.6	164
15	Cardiac morbidity following modern treatment for Hodgkin lymphoma: Supra-additive cardiotoxicity of doxorubicin and radiation therapy. Leukemia and Lymphoma, 2008, 49, 1486-1493.	1.3	144
16	A systematic review examining the effects of therapeutic radioactive iodine on ovarian function and future pregnancy in female thyroid cancer survivors. Clinical Endocrinology, 2008, 69, 479-490.	2.4	143
17	Fertility among female hodgkin lymphoma survivors attempting pregnancy following ABVD chemotherapy. Hematological Oncology, 2007, 25, 11-15.	1.7	134
18	Second Primary Malignancy Risk in Thyroid Cancer Survivors: A Systematic Review and Meta-Analysis. Thyroid, 2007, 17, 1277-1288.	4.5	132

#	Article	IF	CITATIONS
19	Individualized estimates of second cancer risks after contemporary radiation therapy for Hodgkin lymphoma. Cancer, 2007, 110, 2576-2586.	4.1	131
20	A comparison of mantle versus involved-field radiotherapy for Hodgkin's lymphoma: reduction in normal tissue dose and second cancer risk. Radiation Oncology, 2007, 2, 13.	2.7	128
21	Radiation Therapy for Solitary Plasmacytoma and Multiple Myeloma: Guidelines From the International Lymphoma Radiation Oncology Group. International Journal of Radiation Oncology Biology Physics, 2018, 101, 794-808.	0.8	128
22	Results of radiotherapy for epithelial skin cancer of the pinna: the princess margaret hospital experience, 1982–1993. International Journal of Radiation Oncology Biology Physics, 2000, 47, 451-459.	0.8	119
23	Solitary extramedullary plasmacytoma of the head and neckâ€"Longâ€ŧerm outcome analysis of 68 cases. Head and Neck, 2008, 30, 1012-1019.	2.0	119
24	Clinical outcome of anaplastic thyroid carcinoma treated with radiotherapy of once―and twiceâ€daily fractionation regimens. Cancer, 2006, 107, 1786-1792.	4.1	105
25	Parathyroid carcinomaâ€"the princess margaret hospital experience. International Journal of Radiation Oncology Biology Physics, 1998, 41, 569-572.	0.8	99
26	Localized Orbital Mucosa-Associated Lymphoma Tissue Lymphoma Managed With Primary Radiation Therapy: Efficacy and Toxicity. International Journal of Radiation Oncology Biology Physics, 2011, 81, e659-e666.	0.8	94
27	Similar response rates and superior early progressionâ€free survival with gemcitabine, dexamethasone, and cisplatin salvage therapy compared with carmustine, etoposide, cytarabine, and melphalan salvage therapy prior to autologous stem cell transplantation for recurrent or refractory Hodgkin lymphoma, Cancer, 2006, 106, 353-360.	4.1	93
28	Late Cardiac Toxicity After Mediastinal Radiation Therapy for Hodgkin Lymphoma: Contributions of Coronary Artery and Whole Heart Dose-Volume Variables to Risk Prediction. International Journal of Radiation Oncology Biology Physics, 2017, 98, 1116-1123.	0.8	93
29	Central nervous system involvement with multiple myeloma: long term survival can be achieved with radiation, intrathecal chemotherapy, and immunomodulatory agents. British Journal of Haematology, 2013, 162, 483-488.	2.5	89
30	External-beam radiation therapy in the treatment of differentiated thyroid cancer., 1999, 16, 42-49.		88
31	Salvage chemotherapy and autologous stem cell transplantation are inferior for relapsed or refractory primary mediastinal large B-cell lymphoma compared with diffuse large B-cell lymphoma. Leukemia and Lymphoma, 2008, 49, 1329-1336.	1.3	88
32	Hodgkin Lymphoma Across the Age Spectrum: Epidemiology, Therapy, and Late Effects. Seminars in Radiation Oncology, 2010, 20, 30-44.	2.2	86
33	Lentigo Maligna of the Head and Neck. Archives of Dermatology, 1994, 130, 1008.	1.4	85
34	Autotransplants for histologically transformed follicular non-Hodgkin's lymphoma. British Journal of Haematology, 2001, 113, 202-208.	2.5	79
35	CNS Hodgkin lymphoma. Blood, 2008, 112, 1658-1661.	1.4	76
36	The Role of Intensive Therapy and Autologous Blood and Marrow Transplantation for Chemotherapyâ€Sensitive Relapsed and Primary Refractory Nonâ€Hodgkin's Lymphoma: Identification of Major Prognostic Groups. British Journal of Haematology, 1996, 92, 880-889.	2.5	73

#	Article	IF	CITATIONS
37	Radiation therapy for localized low-grade non-Hodgkin's lymphomas. Hematological Oncology, 2005, 23, 10-17.	1.7	73
38	Dietary Iodine Restriction in Preparation for Radioactive Iodine Treatment or Scanning in Well-Differentiated Thyroid Cancer: A Systematic Review. Thyroid, 2010, 20, 1129-1138.	4.5	71
39	Validation of nomogram-revised risk index and comparison with other models for extranodal nasal-type NK/T-cell lymphoma in the modern chemotherapy era: indication for prognostication and clinical decision-making. Leukemia, 2021, 35, 130-142.	7.2	70
40	A systematic review of the gonadal effects of therapeutic radioactive iodine in male thyroid cancer survivors. Clinical Endocrinology, 2008, 68, 610-617.	2.4	69
41	Nonmyeloablative Stem Cell Transplantation for Myelodysplastic Syndrome or Acute Myeloid Leukemia in Patients 60 Years or Older. Biology of Blood and Marrow Transplantation, 2005, 11, 764-772.	2.0	67
42	Clinical dose-volume histogram analysis in predicting radiation pneumonitis in Hodgkin's lymphoma. International Journal of Radiation Oncology Biology Physics, 2006, 66, 223-228.	0.8	65
43	Proliferation measurements with flow cytometry Tpot in cancer of the uterine cervix: Correlation between two laboratories and preliminary clinical results. International Journal of Radiation Oncology Biology Physics, 1995, 32, 1319-1329.	0.8	63
44	A population-based study of cardiac morbidity among Hodgkin lymphoma patients with preexisting heart disease. Blood, 2010, 116, 2237-2240.	1.4	63
45	The Impact of Thyroid Cancer and Post-Surgical Radioactive Iodine Treatment on the Lives of Thyroid Cancer Survivors: A Qualitative Study. PLoS ONE, 2009, 4, e4191.	2.5	61
46	Radiotherapy management for squamous cell carcinoma of the nasal skin: the Princess Margaret Hospital experience. International Journal of Radiation Oncology Biology Physics, 2002, 52, 973-979.	0.8	59
47	Non-hodgkin's lymphoma of the thyroid gland: Prognostic factors and treatment outcome. International Journal of Radiation Oncology Biology Physics, 1993, 27, 599-604.	0.8	53
48	A Systematic Review and Meta-Analysis of Subsequent Malignant Neoplasm Risk After Radioactive lodine Treatment of Thyroid Cancer. Thyroid, 2018, 28, 1662-1673.	4.5	53
49	EXTERNAL RADIATION THERAPY IN THE TREATMENT OF THYROID MALIGNANCY. Endocrinology and Metabolism Clinics of North America, 1996, 25, 141-157.	3.2	50
50	Parathyroid cancer: Outcome analysis of 16 patients treated at the princess margaret hospital. Head and Neck, 2013, 35, 35-39.	2.0	49
51	External Beam Radiation Therapy for Thyroid Cancer. Endocrinology and Metabolism Clinics of North America, 2008, 37, 497-509.	3.2	46
52	Palliation by Low-Dose Local Radiation Therapy for Indolent Non-Hodgkin Lymphoma. International Journal of Radiation Oncology Biology Physics, 2011, 81, e781-e786.	0.8	46
53	Tumour proliferation and apoptosis in human uterine cervix carcinoma II: correlations with clinical outcome. Radiotherapy and Oncology, 1999, 50, 93-101.	0.6	42
54	Randomized Controlled Trial of a Computerized Decision Aid on Adjuvant Radioactive Iodine Treatment for Patients With Early-Stage Papillary Thyroid Cancer. Journal of Clinical Oncology, 2012, 30, 2906-2911.	1.6	40

#	Article	IF	CITATIONS
55	Radiation therapy for Bowen's disease of the skin. International Journal of Radiation Oncology Biology Physics, 2005, 63, 505-510.	0.8	39
56	Prescribing 131 Iodine based on neck uptake produces effective thyroid ablation and reduced hospital stay. Radiotherapy and Oncology, 1998, 47, 325-330.	0.6	38
57	Role of Salvage Radiation Therapy for Patients With Relapsed or Refractory Hodgkin Lymphoma Who Failed Autologous Stem Cell Transplant. International Journal of Radiation Oncology Biology Physics, 2012, 84, e329-e335.	0.8	35
58	Limited-stage mantle cell lymphoma: treatment outcomes at the Princess Margaret Hospital. Leukemia and Lymphoma, 2013, 54, 261-267.	1.3	35
59	Salvage chemotherapy and autologous stem cell transplant in primary refractory diffuse large B-cell lymphoma: outcomes and prognostic factors. Leukemia and Lymphoma, 2012, 53, 836-841.	1.3	34
60	Patients' experiences following local–regional recurrence of thyroid cancer: A qualitative study. Journal of Surgical Oncology, 2013, 108, 47-51.	1.7	34
61	Active breathing control for patients receiving mediastinal radiation therapy for lymphoma: Impact on normal tissue dose. Practical Radiation Oncology, 2014, 4, 174-180.	2.1	34
62	Malignant Teratoma of the Thyroid: Aggressive Chemoradiation Therapy is Required After Surgery. Thyroid, 2003, 13, 401-404.	4.5	30
63	Low-Grade Non-Hodgkin Lymphomas. Seminars in Radiation Oncology, 2007, 17, 198-205.	2.2	30
64	Differentiated Thyroid Cancer with Extrathyroidal Extension: Prognosis and the Role of External Beam Radiotherapy. Journal of Thyroid Research, 2010, 2010, 1-7.	1.3	30
65	Staging and management of localized non-Hodgkin's lymphomas: variations among experts in radiation oncology. International Journal of Radiation Oncology Biology Physics, 2002, 52, 643-651.	0.8	29
66	A comparison of different staging systems predictability of patient outcome. Cancer, 1997, 79, 2414-2423.	4.1	29
67	Outcome of hyperfractionated radiotherapy in chemotherapy-resistant non-Hodgkin's lymphoma. International Journal of Radiation Oncology Biology Physics, 2006, 64, 1183-1187.	0.8	28
68	CLIPI: a new prognostic index for indolent cutaneous B cell lymphoma proposed by the International Extranodal Lymphoma Study Group (IELSG 11). Annals of Hematology, 2011, 90, 401-408.	1.8	28
69	Incidence and risk factors for second cancers after autologous hematopoietic cell transplantation for aggressive non-Hodgkin lymphoma. Leukemia and Lymphoma, 2009, 50, 380-386.	1.3	27
70	Modern Radiation Therapy for Extranodal Nasal-Type NK/T-cell Lymphoma: Risk-Adapted Therapy, Target Volume, and Dose Guidelines from the International Lymphoma Radiation Oncology Group. International Journal of Radiation Oncology Biology Physics, 2021, 110, 1064-1081.	0.8	26
71	Malignant Lymphoma of Mucosa-Associated Lymphoid Tissue of the Lacrimal Gland. American Journal of Clinical Oncology: Cancer Clinical Trials, 2001, 24, 67-70.	1.3	25
72	Incidence of pneumonitis in patients with non-Hodgkin lymphoma receiving chemoimmunotherapy with rituximab. Leukemia and Lymphoma, 2015, 56, 1659-1664.	1.3	24

#	Article	IF	Citations
73	Tumor proliferation and apoptosis in human uterine cervix carcinoma I: correlations between variables. Radiotherapy and Oncology, 1999, 50, 85-92.	0.6	23
74	Impact of chest wall and lung invasion on outcome of stage lâ€"II Hodgkin's lymphoma after combined modality therapy. International Journal of Radiation Oncology Biology Physics, 2003, 57, 1374-1381.	0.8	23
75	High response rate and improvement of long-term survival with combined treatment modalities in patients with poor-risk primary thyroid diffuse large B-cell lymphoma: an International Extranodal Lymphoma Study Group and Intergruppo Italiano Linfomi study. Leukemia and Lymphoma, 2011, 52, 823-832.	1.3	23
76	Second-line salvage chemotherapy for transplant-eligible patients with Hodgkin's lymphoma resistant to platinum-containing first-line salvage chemotherapy. Haematologica, 2012, 97, 751-757.	3.5	23
77	Favorable Overall Survival with Fully Myeloablative Allogeneic Stem Cell Transplantation for Follicular Lymphoma. Biology of Blood and Marrow Transplantation, 2008, 14, 775-782.	2.0	22
78	Thyroid cancer survivors' perceptions of survivorship care follow-up options: a cross-sectional, mixed-methods survey. Supportive Care in Cancer, 2016, 24, 2007-2015.	2.2	22
79	Radiation Therapy for Primary Cutaneous Anaplastic Large Cell Lymphoma: An International Lymphoma Radiation Oncology Group Multi-institutional Experience. International Journal of Radiation Oncology Biology Physics, 2016, 95, 1454-1459.	0.8	21
80	Basis for Physician Recommendations for Adjuvant Radioiodine Therapy in Early-Stage Thyroid Carcinoma: Principal Findings of the Canadian-American Thyroid Cancer Survey. Endocrine Practice, 2008, 14, 175-184.	2.1	19
81	Interrelationship of proliferation and hypoxia in carcinoma of the cervix. International Journal of Radiation Oncology Biology Physics, 2000, 46, 95-99.	0.8	18
82	Proliferation parameters in epidermoid carcinomas of the anal canal. Radiotherapy and Oncology, 2000, 56, 349-353.	0.6	18
83	Radiation Therapy Planning for Early-Stage Hodgkin Lymphoma: Experience of the International Lymphoma Radiation Oncology Group. International Journal of Radiation Oncology Biology Physics, 2015, 92, 144-152.	0.8	18
84	Papillary Thyroid Cancers with Focal Tall Cell Change are as Aggressive as Tall Cell Variants and Should Not be Considered as Low-Risk Disease. Annals of Surgical Oncology, 2019, 26, 2533-2539.	1.5	18
85	Regional Differences in Opinions on Adjuvant Radioactive Iodine Treatment of Thyroid Carcinoma within Canada and the United States. Thyroid, 2007, 17, 1235-1242.	4.5	17
86	Unmet Information Needs of Low-Risk Thyroid Cancer Survivors. Thyroid, 2016, 26, 474-475.	4.5	17
87	Different response to salvage chemotherapy but similar post-transplant outcomes in patients with relapsed and refractory Hodgkin's lymphoma. Haematologica, 2010, 95, 1496-1502.	3.5	16
88	A usability study of a computerized decision aid to help patients with, early stage papillary thyroid carcinoma in, decision-making on adjuvant radioactive iodine treatment. Patient Education and Counseling, 2011, 84, e24-e27.	2.2	16
89	Bleomycin pulmonary toxicity does not adversely affect the outcome of patients with Hodgkin lymphoma. Leukemia and Lymphoma, 2017, 58, 2607-2614.	1.3	16
90	Decision aid on radioactive iodine treatment for early stage papillary thyroid cancer - a randomized controlled trial. Trials, 2010, 11, 81.	1.6	15

#	Article	IF	CITATIONS
91	Role of radiotherapy in patients with early-stage diffuse large B-cell lymphoma of Waldeyer's ring in remission after anthracycline-containing chemotherapy. Leukemia and Lymphoma, 2013, 54, 62-68.	1.3	14
92	Thyroid cancer patient perceptions of radioactive iodine treatment choice: Followâ€up from a decisionâ€aid randomized trial. Cancer, 2015, 121, 3717-3726.	4.1	14
93	Hodgkin's Lymphoma. Current Problems in Cancer, 2006, 30, 107-158.	2.0	12
94	The effects of surgery, radioiodine, and external radiation therapy on the clinical outcome of patients with differentiated thyroid carcinoma. Cancer, 1998, 82, 375-388.	4.1	11
95	Oncocytic Papillary Thyroid Carcinoma and Oncocytic Poorly Differentiated Thyroid Carcinoma: Clinical Features, Uptake, and Response to Radioactive Iodine Therapy, and Outcome. Frontiers in Endocrinology, 2021, 12, 795184.	3.5	11
96	Mucosa-associated lymphoid tissue lymphomas. Current Oncology Reports, 2000, 2, 192-198.	4.0	10
97	The Rationale of Patients with Early-Stage Papillary Thyroid Cancer for Accepting or Rejecting Radioactive Iodine Remnant Ablation. Thyroid, 2013, 23, 246-247.	4.5	9
98	Pretreatment proliferation parameters do not add predictive power to clinical factors in cervical cancer treated with definitive radiation therapy. Clinical Cancer Research, 2003, 9, 4387-95.	7.0	9
99	Quantification of Local Tumor Response to Fractionated Radiation Therapy for Non-Hodgkin Lymphoma Using Weekly 18F-FDG PET/CT Imaging. International Journal of Radiation Oncology Biology Physics, 2010, 76, 850-858.	0.8	8
100	Concerns of low-risk thyroid cancer survivors. Acta Oncol \tilde{A}^3 gica, 2016, 55, 1252-1253.	1.8	8
101	Clinical characteristics and early treatment outcomes of follicular lymphoma in young adults. British Journal of Haematology, 2015, 170, 384-390.	2.5	7
102	Patterns of regional recurrence in papillary thyroid cancer patients with lateral neck metastases undergoing neck dissection. Journal of Otolaryngology - Head and Neck Surgery, 2017, 46, 43.	1.9	7
103	Risk stratification for relapsed/refractory classical Hodgkin lymphoma integrating pretransplant Deauville score and residual metabolic tumor volume. American Journal of Hematology, 2022, 97, 583-591.	4.1	7
104	Influence of age on long-term net survival benefit for early-stage MALT lymphomas treated with radiotherapy: A SEER database analysis (2000–2015). Radiotherapy and Oncology, 2022, 173, 179-187.	0.6	7
105	Exploring the relationship between patients' information preference style and knowledge acquisition process in a computerized patient decision aid randomized controlled trial. BMC Medical Informatics and Decision Making, 2015, 15, 48.	3.0	6
106	Two distinct prognostic groups in advanced-stage Hodgkin lymphoma revealed by the presence and site of bulky disease. Blood Advances, 2020, 4, 2064-2072.	5.2	6
107	Prospective Phase II trial of radiation therapy in localised non-gastric marginal zone lymphoma with prospective evaluation of autoimmunity and Helicobacter pylori status: TROG 05.02/ALLG NHL15. European Journal of Cancer, 2021, 152, 129-138.	2.8	6
108	A single institution experience of extranodal natural killer/T cell lymphoma of nasal type. Leukemia and Lymphoma, 2015, 56, 80-84.	1.3	5

#	Article	IF	Citations
109	Symptom burden in adults with thyroid cancer. Psycho-Oncology, 2018, 27, 2517-2519.	2.3	5
110	The Challenges of Applying Radiation in Primary Central Nervous System Lymphoma. International Journal of Radiation Oncology Biology Physics, 2020, 107, 398-400.	0.8	5
111	Involved field radiotherapy for limited stage Hodgkin lymphoma: balancing treatment efficacy against longâ€ŧerm toxicities. Hematological Oncology, 2009, 27, 115-122.	1.7	4
112	Radiotherapy in mantle cell lymphoma: A literature review. Hematological Oncology, 2020, 38, 223-228.	1.7	4
113	A risk model for relapsed/refractory aggressive NHL integrating clinical risk factors and pretransplant Deauville score. Blood Advances, 2020, 4, 5762-5771.	5.2	3
114	Non-Hodgkin's Lymphoma. , 2016, , 1524-1546.e7.		2
115	A pilot study examining Toronto-area family physician perspectives on thyroid neoplasm evaluation. Journal of Otolaryngology - Head and Neck Surgery, 2019, 48, 24.	1.9	2
116	Side Effects of 131I for Therapy of Differentiated Thyroid Carcinoma. , 2016, , 671-708.		1
117	Effectiveness and tolerability of first-line autologous stem cell transplant and maintenance rituximab for mantle cell lymphoma. Bone Marrow Transplantation, 2018, 53, 347-351.	2.4	1
118	External Radiation Therapy of Medullary Cancer. , 2006, , 605-607.		1
119	Head and Neck Sarcomas and Lymphomas. Medical Radiology, 2009, , 103-115.	0.1	1
120	Failure to Achieve CR with First-Line Treatment Is the Primary Cause of Treatment Failure in T-Cell Lymphoma: The Princess Margaret Cancer Centre Experience. Blood, 2016, 128, 3005-3005.	1.4	1
121	Biochemical modulation of iododeoxyuridine by N6-[4-(morpholinosulfonyl)benzyl]-N6-methyl-2, 6-diaminobenz[cd]indole glucuronate (AG-331) leading to enhanced cytotoxicity. Biochemical Pharmacology, 1995, 50, 55-60.	4.4	0
122	Role of radiation therapy in localised non-Hodgkin's lymphomas. European Journal of Cancer, Supplement, 2003, 1, 41-49.	2.2	0
123	Whole Brain Radiation Is Still the Standard in the Salvage Situation. International Journal of Radiation Oncology Biology Physics, 2020, 107, 403.	0.8	0
124	External Beam Radiotherapy for Thyroid Malignancy. , 2021, , 452-460.e2.		0
125	External Radiation Therapy of Papillary Cancer. , 2006, , 485-489.		0
126	Advances in Radiation Therapy., 2006,, 653-655.		0

#	Article	IF	CITATIONS
127	External Radiation Therapy of Follicular Carcinoma. , 2006, , 545-548.		О
128	External Radiation Therapy of Anaplastic Thyroid Cancer. , 2006, , 641-642.		0
129	Primary Thyroid Lymphoma: A Retrospective IELSG and IIL Analysis of Clinical Characteristics, Prognostic Factors, Treatment Outcome and Somatic Hypermutation for Localized Diffuse Large B-Cell Lymphoma (DLBCL) Blood, 2007, 110, 3432-3432.	1.4	0
130	Salvage Therapy for Relapsed and Refractory Hodgkin Lymphoma. , 2011, , 31-44.		0
131	Non-Hodgkin's Lymphoma. , 2012, , 1545-1572.		0
132	Plasmacytoma and Multiple Myeloma. , 2017, , 85-96.		0
133	Preliminary Results of FDG-PET Scanning after GDP Chemotherapy Prior to Autologous Stem Cell Transplant (ASCT) for Relapsed/Refractory (RR) Lymphoma. Blood, 2016, 128, 4645-4645.	1.4	0